[go: up one dir, main page]

PE20010642A1 - Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas - Google Patents

Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas

Info

Publication number
PE20010642A1
PE20010642A1 PE2000000836A PE0008362000A PE20010642A1 PE 20010642 A1 PE20010642 A1 PE 20010642A1 PE 2000000836 A PE2000000836 A PE 2000000836A PE 0008362000 A PE0008362000 A PE 0008362000A PE 20010642 A1 PE20010642 A1 PE 20010642A1
Authority
PE
Peru
Prior art keywords
combination
pramipexol
clonidine
treatment
restless legs
Prior art date
Application number
PE2000000836A
Other languages
English (en)
Inventor
Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20010642A1 publication Critical patent/PE20010642A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41681,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMBINACION QUE COMPRENDE a)DE 0,01 mg A 1 mg DE CLONIDINA O 2-(2,6-DICLORO-ANILINO)-4,5-DIHIDRO-IMIDAZOL; b)DE 0,05 A 2 mg DE PRAMIPEXOL O (S)-2-AMINO-6-n-PROPILAMINO-4,5,6,7-TETRAHIDRO-BENZOTIAZOL. LA COMBINACION SE FORMULA EN TABLETAS, CAPSULAS, EMPLASTO TRANSDERMICO, UTILIZANDOSE LAS SUSTANCIAS MEZCLADAS O SEPARADAS. EL PRAMIPEXOL ES UN AGENTE AGONISTA D2/D3 (ANTAGONISTA DE DOPAMINA) Y LA CLONIDINA ES UN AGENTE ANTIHIPERTONICO Y MIOTICO POR LO QUE LA COMBINACION PUEDE SER UTIL PARA EL TRATAMIENTO DEL SINDROME DE PIERNAS INQUIETAS (RLS)
PE2000000836A 1999-08-19 2000-08-17 Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas PE20010642A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19938825A DE19938825A1 (de) 1999-08-19 1999-08-19 Wirkstoffkombination mit Clonidin

Publications (1)

Publication Number Publication Date
PE20010642A1 true PE20010642A1 (es) 2001-06-08

Family

ID=7918574

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000836A PE20010642A1 (es) 1999-08-19 2000-08-17 Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas

Country Status (19)

Country Link
US (1) US20020010201A1 (es)
EP (1) EP1210081A2 (es)
JP (1) JP2003507420A (es)
KR (1) KR20020060163A (es)
AR (1) AR025330A1 (es)
AU (1) AU6440600A (es)
BR (1) BR0013353A (es)
CA (1) CA2376606A1 (es)
CO (1) CO5200840A1 (es)
CZ (1) CZ2002515A3 (es)
DE (1) DE19938825A1 (es)
IL (1) IL147741A0 (es)
MX (1) MXPA02001138A (es)
NO (1) NO20020793D0 (es)
PE (1) PE20010642A1 (es)
PL (1) PL353358A1 (es)
TR (1) TR200200449T2 (es)
UY (1) UY26293A1 (es)
WO (1) WO2001013902A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AU2002360600B2 (en) 2001-12-11 2007-11-29 University Of Virginia Patent Foundation Use of pramipexole to treat amyotrophic lateral sclerosis
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
ES2310258T5 (es) 2002-08-30 2012-05-31 Kyowa Hakko Kogyo Co., Ltd. Antagonistas de los receptores de adenosina A2A para tratar el síndrome de piernas inquietas o mioclono nocturno
SI1426049T1 (en) * 2002-12-02 2005-08-31 Sanol Arznei Schwarz Gmbh Iontophoretic delivery of rotigotine for the treatment of Parkinson's disease
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ES2379117T3 (es) 2006-05-16 2012-04-20 Knopp Neurosciences, Inc. Composiciones de R(+) y S(-) pramipexol y métodos de utilización de las mismas
WO2008009664A2 (en) * 2006-07-19 2008-01-24 Boehringer Ingelheim International Gmbh Treatment of pain
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EP2137171A4 (en) 2007-03-14 2010-05-19 Knopp Neurosciences Inc SYNTHESIS OF BENZOTHIAZOLE DIAMINES SUBSTITUTED AND PURIFIED FROM THE CHIRAL PERSPECTIVE
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
CA2734491A1 (en) 2008-08-19 2010-02-25 Knopp Neurosciences, Inc. Compositions and methods of using (r)-pramipexole
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
CA2896055C (en) * 2012-12-28 2021-02-16 Noven Pharmaceuticals, Inc. Compositions and methods for transdermal delivery of amphetamine and clonidine
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
SMT202100119T1 (it) 2013-07-12 2021-05-07 Knopp Biosciences Llc Trattamento dei livelli elevati di eosinofili e/o basofili
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
US6001861A (en) * 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
AU3490300A (en) * 1999-03-12 2000-10-04 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Also Published As

Publication number Publication date
NO20020793L (no) 2002-02-18
CZ2002515A3 (cs) 2002-05-15
CO5200840A1 (es) 2002-09-27
UY26293A1 (es) 2001-04-30
TR200200449T2 (tr) 2002-08-21
AR025330A1 (es) 2002-11-20
JP2003507420A (ja) 2003-02-25
NO20020793D0 (no) 2002-02-18
EP1210081A2 (de) 2002-06-05
PL353358A1 (en) 2003-11-17
WO2001013902A2 (de) 2001-03-01
MXPA02001138A (es) 2002-10-31
US20020010201A1 (en) 2002-01-24
IL147741A0 (en) 2002-08-14
BR0013353A (pt) 2002-04-23
WO2001013902A3 (de) 2001-08-23
CA2376606A1 (en) 2001-03-01
KR20020060163A (ko) 2002-07-16
DE19938825A1 (de) 2001-04-26
AU6440600A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
PE20010642A1 (es) Combinacion de pramipexol y clonidina para el tratamiento del sindrome de piernas inquietas
PA8502901A1 (es) Tratamiento de combinacion con il-1ra y compuestos que inhiben el procesamiento y la liberacion de il-1
CO5261563A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
NO20075427L (no) Ny farmasoytisk formulering inneholdende et biguanid og et tiazolidindionderivat
UY26296A1 (es) Tratamiento medicamentoso del síndrome de piernas inquietas
ATE493130T1 (de) Opioid enthaltende arzneiform gegen missbrauch
PE20020770A1 (es) Formulaciones de entecavir de dosis bajas y uso
PE20010817A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
UY26391A1 (es) Inhibidores sglt2 de glucosidos de c-arilo y metodo
ECSP077241A (es) Formulación en comprimidos de liberación extendida que contiene pramipexol o una sal farmacéuticamente aceptable del mismo, método para su fabricación y su uso
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EE9900288A (et) Peroraalselt manustatava farmatseutilise kompositsiooni kasutamine meeste erektiilse talitlushäire raviks ettenähtud ravimi valmistamiseks
PE20050775A1 (es) Formulaciones que comprenden multiparticulas de liberacion controlada
MX9203444A (es) Medicamentos.
PE83199A1 (es) Composicion farmaceutica de tiazolidinadiona y biguanida para el tratamiento de la diabetes
ECSP055569A (es) Forma de dosificación de pramipexol en una dosis única diaria
PE20081297A1 (es) Forma de dosificacion transdermica resistente a la manipulacion
AR038535A1 (es) Formulaciones farmaceuticas de agentes antineoplasicos y procesos para prepararlos y usarlos
ATE401314T1 (de) Benzodiazepin-derivate als gamma-secretase inhibitoren
CO5011043A1 (es) Composicion farmaceutica que contiene un compuesto inhibidor ace y estabilizador, tabletas que la contienen y proceso para estabilizar inhibidores de ace
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
PE20060594A1 (es) Composicion farmaceutica que contiene un agonista de ppar
UY27031A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar disfunción sexual

Legal Events

Date Code Title Description
FA Abandonment or withdrawal